RxDoctor Payments Data

Brad White, MD

Urology · Saint Louis, MONPI 1205810512

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,253 of the $8,657 with a category attached, or 72.2%. 48 manufacturers reported payments, led by Histosonics, Inc. at 24.2% of the total. 2025 is the largest year on record at $3,017, 4.8 times the $624 reported in 2019.

$8,657in general payments, 2019–2025

Across 285 payments — averaging $30.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Histosonics, Inc.$2K
  • AbbVie$509
  • Boston Scientific$505
  • Urogen Pharma, Inc.$449
  • Pfizer$438
  • Intuitive Surgical$432
  • plus $4K from 42 others

What the payments were for

  • Travel & lodging$2,09424%
  • Food & beverage$6,25372%
  • Education$3104%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,657 in reported general payments places this provider in the 75th percentile of 250 urology providers in Missouri.

See all urology providers in Missouri

Medicare billing

Part B allowed, 2024
$263,540
Medicare patients
656
Services billed
10,159

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron195$145,006
OrgovyxRelugolix25$65,651
GemtesaVibegron46$27,565
Mirabegron ErMirabegron21$18,673
Tamsulosin Hcl1,263$13,959
Finasteride1,278$13,602
Amitriptyline Hcl143$2,009
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst70$1,944
Potassium Citrate ErPotassium Citrate11$1,421
Solifenacin Succinate35$1,001
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim153$969
Silodosin12$956
Tadalafil15$885
Trimethoprim11$885
Alfuzosin Hcl ErAlfuzosin Hcl43$626

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$412$145,006195 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$134$93,21671 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 250 urology providers in Missouri.

Other urology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →